Intranasal azelastine. A review of its efficacy in the management of allergic rhinitis

Drugs

Volumn 56, Issue 1, 1998, Pages 91-114

  McNeely, Wendy ^a   Wiseman, Lynda R ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; AZELASTINE; BECLOMETASONE; BUDESONIDE; CETIRIZINE; EBASTINE; LEVOCABASTINE; LORATADINE; TERFENADINE;

ALLERGIC RHINITIS; ANTIINFLAMMATORY ACTIVITY; CLINICAL TRIAL; DRUG EFFICACY; DRUG FORMULATION; HUMAN; INTRANASAL DRUG ADMINISTRATION; NOSE CONGESTION; ORAL DRUG ADMINISTRATION; REVIEW; RHINITIS; SEDATION; SKIN IRRITATION; SYMPTOM; TASTE DISORDER;

EID: 0031821362     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199856010-00011     Document Type: Review

References (100)

1. 1+-antagonists. Clin Exp Allergy 1990; 20 Suppl. 2: 3-17
2. 1-receptor antagonists. Ann Allergy 1991 Jan; 66: 5-21
3. McTavish D, Sorkin EM. Azelasline: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs 1989 Nov; 38: 778-800
4. Thomas KE, Ollier S, Ferguson H, et al. The effect of intranasal azelastine, Rhinolast (Rm), on nasal airways obstruction and sneezing following provocation testing with histamine and allergen. Clin Exp Allergy 1992 Jun; 22: 642-7
5. 2-macroglobulin into human nasal airways. Clin Exp Allergy 1997 Apr; 27: 438-44
6. Spaeth J, Schultze V, Klimek L, et al. Azelastine reduces histamine-induced swelling of nasal mucosa. J Otorhinolaryngol Relat Spec 1996 May-Jun; 58: 157-63
7. Horak F, Jäger S, Toth J, et al. Azelastine in pollen-induced allergic rhinitis: a pharmacodynamic study of onset of action and efficacy. Drug Invest 1994 Jan; 7: 34-40
8. Wang D, Clement P, Smitz J, et al. The activity of recent anti-allergic drugs in the treatment of seasonal allergic rhinitis. Acta Otorhinolaryngol Belg 1996; 50: 25-32
9. Pronzato C, Ricca V, Varese P, et al. Evaluation of antiallergic activity of azelastine nasal spray (abstract). Allergy 1995; 50 Suppl. 26: 69
10. Ciprandi G, Pronzato C, Passalacqua G, et al. Topical azelasline reduces eosinophil activation and intercellular adhesion molecule-1 expression on nasal epithelial cells: an antiallergic activity. J Allergy Clin Immunot 1996 Dec; 98 (Pt 1): 1088-96
11. Roger Reig A, Roger Barri JM. The effect of topical azelastine and N-acetyl aspartyl-glutamate (NAAGA) on allergen nasal provocation test (NPT) [abstract]. Allergy 1995; 50 Suppl. 26: 196
12. Bahre M, Klimek L, Mölich J, et al. Azelastine reduces release of eosinophil cationic protein (ECP) [abstract]. Allergy 1995; 50 Suppl. 26: 102
13. Mösges R, Klimek L, Bahre M, et al. Azelastine reduces mediators of nasal inflammation in patients with nasal polyposis [abstract]. Allergy 1997; 52 Suppl. 37: 204
14. Taniguchi K, Masuda Y, Takanaka K. Action sites of antiallergic drugs on human neutrophils. Jpn J Pharmacol 1990 Jan; 52: 101-8
15. Busse W, Randlev B, Sedgwick J. The effect of azelastine on neutrophil and eosinophil generation of superoxide. J Allergy Clin Immunol 1989 Feb; 83 (2 Pt 1): 400-5
16. Akamatsu H, Miyachi Y, Asada Y, et al. Effects of azelastine on neutrophil chemotaxis, phagocytosis and oxygen radical generation. Jpn J Pharmacol 1991 Dec; 57: 583-9
17. Umeki S. Effects of anti-allergic drugs on human neutrophil superoxide-generating NADPH oxidase. Biochem Pharmacol 1992 Mar 3; 43: 1109-17
18. Kurosawa M, Hanawa K, Kobayashi S, et al. Inhibitory effects of azelastine on superoxide anion generation from activated inflammatory cells measured by a simple chemiluminescence method. Arzneimittel Forschung 1990 Jul; 40: 767-70
19. Hojo M, Hamasaki Y, Fujita I, et al. Effects of anti-allergy drugs on fMet-Leu-Phe-stimulated superoxide generation in human neutrophils. Ann Allergy 1994 Jul; 73: 21-6
20. Renesio P, Balloy V, Vargaftig BB, et al. Interference of antiinflammatory and anti-asthmatic drugs with neutrophil-mediated platelet activation: singularity of azelastine. Br J Pharmacol 1991 Jun; 103: 1435-40
21. Ventura MT, Bruno LM, Iacobelli A, et al. Fosinophil chemotactic activity in parietaria allergic patients: in vitro and in vivo azelasline modulation (abstract). Allergy 1997; 52 Suppl. 37: 111
22. 2+ influx, actin polymerization and release of eusmophit cationic protein of an eosinophilic leukaemia cell line EoL-1. Curr Med Res Opin 1993; 13 (3): 163-74
23. 1-blockers. Jpn J Pharmacol 1991 Dec; 57: 473-82
24. Guinnepain MT, Macquin-Mavier I, Verrière JL. Histamine skin prick tests during azelastine nasal spray treatment in healthy adults [abstract]. Allergy 1995; 50 Suppl. 26: 102
25. Baumgarten CR, Petzold U, Dokic D, et al. Modification of allergen-induced symptoms and mediator release by intranasal azelastine. Pharmacol Ther 1994 Feb; 3: 43-51
26. Meltzer EO. The pharmacological basis for the treatment of perennial allergic rhinitis and non-allergic rhinitis with topical corticosteroids. Allergy 1997; 52 Suppl. 36: 33-40
27. Ciprandi G, Ricca V, Passalacqua G, et al. Seasonal rhinitis and azelastine: long- or short-term treatment? J Allergy Clin Immunol 1997 Mar; 99: 301-7
28. Ford-Hutchinson AW, Bray MA, Doig MV, et al. Leukotriene B, a potent chemokmetic and aggregating substance released from polymorphonuclear leukocytes. Nature 1980 Jul 17; 286: 264-5
29. Busse WW. The role of leukotrienes in asthma and allergic rhinitis. Clin Exp Allergy 1996 Aug; 26: 868-79
30. 4 is a potent and stereospecific stimulator of neutrophil chemotaxis and adherence. Blood 1981 Sep; 58 (3): 658-61
31. Curnuue JT. Activation of human neutrophil nicotinamide adenine dinucleotide phosphate, reduced (triphosphopyridine nucleotide, reduced) oxidase by arachidonic acid in a cell-free system. J Clin Invest 1985 May; 75: 1740-3
32. McPhail LC, Shirley PS, Clayton CC, et al. Activation of the respiratory hurst enzyme from human neutrophils in a cell-free system: evidence for a soluble cofactor. J Clin Invest 1985 May; 75: 1735-9
33. Rasmussen H, Kojima I, Kojima K, et al. Calcium as intracellular messenger: sensitivity modulation, C-kinase pathway, and sustained cellular response. Adv Cyclic Nucleotide Protein Phosphorylation Res 1984; 18: 159-93
34. Amos WMG. Hypersensitivity andautoimmunity. In: Basic Immunology. 1st ed. London:, 1981: 133-51
35. Kurosawa M. Inhibitory effects of azelastine on protein kinase C and diphosphoinositide kinase in rat mast cells. Arzneimittel Forschung 1990 Feb; 40: 162-5
36. Fanous K, Garay RP. Azelastine and allergen transduction signal in MC9 mast cells. Naunyn Schmiedebergs Arch Pharmacol 1993 Nov; 348: 515-9
37. Middleton Jr E, Ferriola P, Drzewiecki G, et al. The effect of azelastine and some other antiasthmatic and antiallergic drugs on calmodulin and protein kinase C. Agents Actions 1989 Aug; 28: 9-15
38. Hide I, Toriu N, Nuibe T, et al. Suppression of TNF-α secretion by azelastine in a rat mast (RBL-2H3) cell line: evidence for differential regulation of TNF-α release, transcription, and degranulation. J Immunol 1997 Sep 15; 159: 2932-40
39. Hindmarch I. Psychometric aspects of antihistamines. Allergy 1995; 50 Suppl. 24: 48-54
40. Spaeth J, Klimek L, Mösges R. Sedation in allergic rhinitis is caused by the condition and not by antihistamine treatment. Allergy 1996 Dec; 51: 893-906
41. Kaneko T, Kitahara A, Ozaki S, et al. Effects of azelastine hydrochloride, a novel anti-allergic drug, on the central nervous system. Arzneimittel Forschung 1981; 31: 1206-12
42. Wallace Laboratories. Azelastine hydrochloride nasal spray prescribing information. New Jersey, USA, 1997
43. ASTA medica AG. Azelastine product monograph. Frankfurt am Main, Germany, May 1997
44. Kisicki JC, Howard JR, Riethmuller-Winzen H, et al. Azelastine nasal spray - twenty-nine day tolerability and safety study in healthy subjects. Asia Pharma AG / Carter-Wallace Ltd. CP-90-254; Jul 02 1990 (Data on file)
45. Weliky I, Howard JR, Wichmann JK. Absolute bioavailability (AB) and pharmacokinetics (PK) of azelastine (AZ) [abstract]. Pharm Res 1990 Sep; 7 Suppl.: S247
46. Riethmüller-Winzen H, Peter G, Büker KM, et al. Tolerability. pharmacokinetics and dose linearity of azelastine hydrochloride in healthy subjects. Arzneimittel Forschung 1994 Oct; 44: 1136-40
47. Kisicki JC, Herman R, Niebch G, et al. Amendment No. 1 to the report: azelastine nasal spray - twenty-nine day tolerability and safety study in healthy subjects. Asta Pharma AG / Carter-Wallace Ltd. CP-90-254; Apr 23 1993 (Data on file)
48. Peter G, Romeis P, Borbe HO, et al. Tolerability and pharmacokinetics of single and multiple doses of azelastine hydrochloride in elderly volunteers. Arzneimittel Forschung 1995 May; 45: 576-81
49. Hirata-Dulas CAI, Awni WM, Weliky I, et al. Disposition of azelastine (AZ) and desmethylazelastine (DAZ) in patients with hepatic dysfunction (HEP) and renal insufficiency (RI) [abstract]. Pharm Res 1992 Oct; 9 Suppl.: S318
50. Mackay IS. Classification and differential diagnosis of rhinitis. Eur Resp Rev 1994; 4 (20): 245-7
51. 1-receptor antagonists in the management of allergic rhinitis: a comparative review. Clin Immunother 1994 Nov; 2: 352-75
52. Meltzer EO, Weiler JM, Dockhom RJ, et al. Azelastine nasal spray in the management of seasonal allergic rhinitis. Ann Allergy 1994 Apr; 72: 354-9
53. LaForce C, Dockhorn RJ, Prenner BM, et al. Safety and efficacy of azelastine nasal spray (Astelin NS) for seasonal allergic rhinitis: a 4-week comparative multicenter trial. Ann Allergy Asthma Immunol 1996 Feb; 76: 181-8
54. Ratner PH, Findlay SR, Hampel Jr JF, et al. A double-blind, controlled trial to assess the safety and efficacy of azelastine nasal spray in seasonal allergic rhinitis. J Allergy Clin Immunol 1994 Nov; 94: 818-25
55. Weiler JM, Meltzer EO, Benson PM, et al. A dose-ranging study of the efficacy and safety of azelastine nasal spray in the treatment of seasonal allergic rhinitis with an acute model. J Allergy Clin Immunol 1994 Dec; 94 (Pt 1): 972-80
56. Weiler JM, Meltzer EO. Azelastine nasal spray as adjunctive therapy to azelastine tablets in the management of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 1997 Oct; 79: 327-32
57. LaForce CF. Study protocol on azelasline. Reply [letter]. Ann Allergy Asthma Immunol 1997 Feb; 78: 244
58. Grossman J, Meltzer E, Pearlman D, et al. Onset of action and patient acceptance of azelastine in a nasal spray formulation (abstract no. 251). Presented at the XVIth International Conress of Allergy and Immunology, 1997 Oct 19-24; Cancun, Mexico
59. Mösges R, Spaeth J, Conrad F, et al. Azelastine nasal spray in the allergological practice (in German). Aktuel Neurol 1995; 3: 173-6
60. Gastpar H, Dorow P, Aurich R et al. Investigation of long-term efficacy and tolerability of azelastine nasal spray in the treatment of perennial allergic rhinitis. Arzneimittel Forschung 1993 Jul; 43: 771-6
61. Storms WW, Pearlman DS, Chervinsky P, et al. Effectiveness of azelastine nasal solution in seasonal allergic rhinitis. Ear Nose Throat J 1994 Jun; 73: 382-6,390-4
62. Cua-Lim F, Cua PE, Perez A, et al. The efficacy and safety of azelastine nasal spray in perennial allergic rhinitis in Pilipinos [abstract]. Allergy 1997; 52 Suppl. 37: 209
63. Aun WT, Almeida CIR, Almeida WL, et al. Azelasline nasal spray in the treatment of perennial allergic rhinitis -Brazilian multicentric study [abstract]. Allergy 1997; 52 Suppl. 37: 201
64. Wober W, Diez Crespo C, Bähre M. Evaluation of the drug monitoring programme of azelastine hydrochloride nasal spray in the treatment of allergic rhinitis in children under 13 years of age. Arzneimittel Forschung 1997 Jul; 47: 841-4
65. Piggot PV. Expert reoprt on the clinical documentation azelastine nasal spray 0.1% for children. Asia Medica (Germany). 1996, project/report number A-05610/6800000013 (Data on file)
66. Bahre M, Gröger J, Roloff A. Assessment of the efficacy and safety of azelastine nasal spray in seasonal rhinitis in 6 to 12 years old children. Abstract at 4th International Conference on Pediatric ENT, Siena, Oct 1996
67. Baehre M, Herman D, Le Gal M, et al. Azelastine nasal spray in children with perennial allergic rhinitis [abstract]. Allergy 1996; 51 Suppl. 31: 157-8
68. Herman D, Garay R, Le Gal M. A randomized double-blind placebo controlled study of azelastine nasal spray in children with perennial rhinitis. Int J Pediatr Otorhinolaryngol 1997 Feb 14; 39: 1-8
69. Marin Molina AM, Botey Sala J, Eseverri Asin JL, et al. Investigation of the efficacy and tolerance of azelastine nasal spray versus budesonide aqueous solution in the treatment of children with perennial allergic rhinitis. Allergol Immunopathol 1995; 24 Suppl. 1
70. Santoro Jr M, Rosario Filho NA, Kovalhik L, et al. Evaluación de la eficacia y tolerancia del spray nasal de azelastina en niños con rinilis alérgica perenne. Pediatria Moderna 1996 Oct; 23 (6): 691-6
71. Boné Calvo J, Botey Sala J, Caballero Gómez L, et al. Long term safety and efficacy of azelastine HCl nasal spray in the treatment of children with perennial allergic rhinitis. Acta Paediatr Espanola 1996; 54 (10): 750-64
72. Dechant KL, Goa KL. Levocabastine: a review of its pharmacological properties and therapeutic potential as a topical antihistamine in allergic rhinitis and conjunctivitis. Drugs 1991; 41 (2): 202-24
73. Klimek L, Bahre M, Conrad F, et al. Oral, nasal or combined treatment of seasonal allergic rhinitis? A double-blind comparative trial with azelasline nasal spray and azelastine tablets [abstract]. Allergy 1996; 51 Suppl. 31: 156
74. Mösges R, Spaeth J, Klimek L. Efficacy and tolerability of levocabastine and azelastine nasal sprays for the treatment of allergic rhinitis. Mediators Inflamm 1995 May; 4 Suppl. 1: S11-5
75. Charpin D, Godard P, Garay RP, et al. A multicenter clinical study of the efficacy and tolerabilily of azelastine nasal spray in the treatment of seasonal allergic rhinitis: a comparison with oral cetirizine. Eur Arch Otorhinolaryngol 1995 Dec; 252: 455-8
76. Passali D, Piragine F. A comparison of azelastine nasal spray and cetirizine tablets in the treatment of allergic rhinitis. J Int Med Res 1994 Jan-Feb; 22: 17-23
77. Conde Hernández DJ, Palma Aqilar JL, Delgada Romero J. Comparison of azelastine nasal spray and oral ebastine in treating seasonal allergic rhinitis. Curr Med Res Opin 1995; 13 (6): 299-304
78. Gambardella R. A comparison of the efficacy of azelastine nasal spray and loratidine tablets in the treatment of seasonal allergic rhinitis. J Int Med Res 1993 Sep-Oct; 21: 268-75
79. Miniti A, Mello Jr JF. A comparison of efficacy and tolerability of azelastine nasal spray and loratadine tablets in patients with perennial allergic rhinitis [abstract]. Allergy 1997; 52 Suppl. 37: 201
80. Mösges R, Dostal M, Grohmann E, et al. Ist bei der allergischen Rhinitis die Therapie mit Azelastin-Nasenspray wirkungsäquivalent der systemischen Therapie mit Loratadin-Tabletten? Topische Therapie der allergischen Rhinitis; Referate und Vortrage des Aachener gesprache zur Allergologie 1993: 121-129
81. Gastpar H, Nolte D, Aurich R, et al. Comparative efficacy of azelasline nasal spray and terfenadine in seasonal and perennial rhinitis. Allergy 1994 Mar; 49: 152-8
82. Newson-Smith G, Powell M, Baehre M, et al. A placebo controlled study comparing the efficacy of intranasal azelastine and beclomethasone in the treatment of seasonal allergic rhinitis. Eur Arch Otorhinolaryngol 1997 May; 254: 236-41
83. Davies RJ, Lund VJ, Harten-Ash VJ. The effect of intranasal azelastine and beclomethasone on the symptoms and signs of nasal allergy in patients with perennial allergic rhinitis. Rhinology 1993 Dec; 31: 159-64
84. Pelucchi A, Chiapparino A, Mastropasqua B, et al. Effect of intranasal azelastine and beclomethasone dipropionate on nasal symptoms, nasal cytology, and bronchial responsiveness to methacholine in allergic rhinitis in response to grass pollens. J Allergy Clin Immunol 1995 Feb; 95: 515-23
85. Gastpar H, Aurich R, Petzold U, et al. Intranasal treatment of perennial allergic rhinitis: comparison of azelastine nasal spray and budesonide nasal aerosol. Arzneimittel Forschung 1993 Apr; 43: 475-9
86. Dorow P, Aurich R, Petzold U. Efficacy and tolerability of azelastine nasal spray in patients with allergic rhinitis compared to placebo and budesonide. Arzneimittel Forschung 1993 Aug; 43: 909-12. Summary in 2 parts (Pt B)
87. Stern MA, Ridout S, Campbell LM. Budesonide (Rhinocorl® Aqua) versus azelastine (Rhinolast®) in a placebo controlled efficacy study in perennial allergic rhinitis (abstract). In: 1996 Annual Meeting American College of Allergy, Asthma & Immunology. :, 1996: 47
88. Wober W, Diez Crespo C, Bahre M. Efficacy and tolerability of azelastine nasal spray in the treatment of allergic rhinitis: large scale experience in community practice. Curr Med Res Opin 1997; 13 (10): 617-26
89. MacMahon MT, Newson-Smith G, Garnham SP, et al. Intranasal azelastine in seasonal allergic rhinitis (abstract). 95th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics New Orleans, Louisiana 1994 Mar 30-Apr 1: 184
90. Lassig W, Wober W, Höflich C, et al. Topical therapy of allergic-rhinitis in childhood: Allergodil nasal spray-non-sedating in children. Curr Med Res Opin 1996; 13 (7): 391-5
91. Lund VJ. Practical application of the International Consensus on the Management of Rhinitis. Clin Immunother 1995 Oct; 4: 270-8
92. Wiseman LR, Faulds D. Ebastine: a review of its pharmacological properties and clinical efficacy in the treatment of allergic disorders. Drugs 1996 Feb; 51: 260-77
93. Bronsky EA, Meltzer EO, Perhach JL, et al. Cardiac safety of azelastine following 8 weeks of intra-nasal administration (abstract). J Allergy Clin Immunol 1997 Jan; 99 (Pt 2): S445
94. Datapharm Publications Ltd. ABPI compendium of data sheets and summaries of product characteristics 1996-97 (p59-60). Rhinolast nasal spray, ASTA Medica Ltd, 1996
95. Medicines Control Agency. Medically targeted abridged application PL 08336/0077 Name of product: Rhinolast Nasal Spray. Asia Medica Ltd (Cambridge, UK) 1996; UK Marketing Authorisation: PL 08336/0039 (Data on file)
96. Spector SL. Overview of comorbid associations of allergic rhinitis. J Allergy Clin Immunol 1997 Feb; 99: S773-80
97. Creticos PS. Allergic rhinitis. In: Busse WW, Holgate ST, editors. Asthma and rhinitis, first ed. Oxford. Blackwell Scientific Publications, 1995: 1394-403
98. Parikh A, Scadding GK. Seasonal allergic rhinitis. BMJ 1997 May 10; 314: 1392-5
99. Fornadley JA, Corey JP, Osguthorpe JD, et al. Allergic rhinitis: clinical practice guideline. Otolaryngol Head Neck Surg 1996 Jul; 115: 115-22
100. Noble S, McTavish D. Levocabastine, an update of its pharmacology, clinical efficacy and tolerability in the topical treatment of allergic rhinitis and conjunctivitis. Drugs 1995 Dec; 50: 1032-49